Unilever has abandoned its buyout bid for GlaxoSmithKline’s consumer health division after the UK pharma company rejected a £50bn ($67.8bn) offer.
That means GSK looks set to proceed with the spin-out and stock market flotation of the division this summer as...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
